TROX has dropped 26% over the past month to $3.99, and the Street's response has been a sequence of target cuts that shows no sign of stopping.
The analyst story here is unusually bearish, and it is worth stating plainly. Mizuho cut its target to $4.50 from $5.50 this week while keeping an Underperform rating. JP Morgan downgraded to Underweight in August, slashing its target from $7.00 to $5.00. Goldman Sachs has held a Sell since May, when it flipped from Buy and set a $9.00 target, now cut further to $6.50. The mean price target of $6.625 sits well above the current price, but that figure flatters: virtually every recent move has been a downward revision, and the directional drift is unmistakeable. Bears point to pricing headwinds from competitor capacity expansions and macro weakness in TROX's core end markets. The bull case, leaner now, rests on titanium dioxide demand recovery and what the company describes as structural competitive advantages in pigment and zircon. With a negative P/E of -6.9 and a price-to-book of 0.60, the stock is genuinely cheap on book value, though quality metrics give little comfort: the ORTEX short score ranks in just the 4th percentile of the universe, reflecting deep fundamental stress.
Short interest tells a nuanced story rather than a crowded-short one. At 12.4% of the free float, the level is elevated, but shorts have actually been trimming: shares short have fallen roughly 14% over the past month, from around 23 million in late August to under 20 million now. The borrow market is loose. Availability is running near 749% of short interest, meaning there are roughly seven shares available in the lending pool for every one currently borrowed. Cost to borrow is minimal at 0.53%. None of that points to a squeeze setup; the short base is large but not extreme, and borrowing this name costs almost nothing. The ORTEX short score of 62.4 has been remarkably stable across the past two weeks, oscillating narrowly around that level without a directional push in either direction.
Options positioning has shifted slightly more defensive as the stock has fallen. The put/call ratio is running at 0.20, above its 20-day average of 0.17 by about 1.5 standard deviations. That is not a dramatic hedging signal, but it marks a shift from September's earlier readings, which were clustered nearer the yearly low of 0.07. The 52-week high on the PCR is 0.62, so today's reading is still far from peak fear, more a modest uptick in protection-buying than outright alarm.
The ownership picture adds one notable data point. FMR (Fidelity) filed an amended Schedule 13G in June 2025 showing its stake had collapsed from 9.6% to just 0.2%. That is a significant exit by a major passive holder, one that may have contributed to the sustained selling pressure across this period. Dimensional Fund Advisors, Van Eck, and American Century have all added shares recently, providing some offset, but those are smaller, more systematic flows. National Industrialization Company remains the anchor holder at 23.5% of shares, unchanged. No 13D activist is on the register; the disclosure note from ORTEX reminds that stakes are as-last-disclosed around the 5% threshold and holders dropping below that level may not file again.
The recent earnings history adds important context. TROX has surprised positively: the August print triggered a 17% next-day gain, and an earlier event the same month produced an 11% move. The next report is due on 4 November, roughly five weeks away. With the stock having given back all those post-earnings gains and more, the question going into November is whether the Q3 print and outlook can interrupt what has become a steady downgrade cycle, or whether the pricing environment forces another round of estimate reductions from a Street already positioned bearishly.
What to watch: the pace of analyst target revisions into the Q3 report, any shift in the borrow market as the print approaches, and whether the recent short covering extends or reverses once November's numbers are on the table.
See the live data behind this article on ORTEX.
Open TROX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
